Arca
Skip to content
Tools
Tools

Chondrosarcoma

Drug research and approvals for chondrosarcoma: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.

As of Nov 18, 2026, 19 studies of chondrosarcoma are recruiting on ClinicalTrials.gov, Health Canada has authorized 2 drug trials for it since 2013, and FDA has 0 approved and 3 open orphan designations naming it.

  • Recruiting worldwide: 19
  • Trials authorized in Canada: 2
  • FDA orphan approvals: 0
  • EU medicines: 0

Recruiting now

Newest start dates first, of 19 recruiting on ClinicalTrials.gov ↗

Drug pipeline

8 in phase 2, 2 in phase 1 or earlier; from ChEMBL's drug indications, furthest stage reached for this condition
Everolimus
Phase 2 FK506-binding protein 1A inhibitor
Pazopanib
Phase 2 Macrophage colony stimulating factor receptor inhibitor
Ivosidenib
Phase 2 Isocitrate dehydrogenase [NADP] cytoplasmic inhibitor
Imatinib
Phase 2 Tyrosine-protein kinase ABL inhibitor
Catequentinib
Phase 2 Vascular endothelial growth factor receptor 2 inhibitor
Patidegib
Phase 2 Smoothened homolog antagonist
Drozitumab
Phase 2 Tumor necrosis factor receptor superfamily member 10B agonist
Ozekibart
Phase 2
Zoledronic acid anhydrous
Phase 1 Farnesyl diphosphate synthase inhibitor
Tanespimycin
Phase 1 Heat shock protein HSP90 inhibitor

How its trials ended

84 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrong

Of the 14 whose ending is known, 36% met their primary endpoint, 14% missed it and 50% stopped early.

  • Ongoing3946%
  • Completed, result not reported2833%
  • Met its primary endpoint56%
  • Stopped: other or unclear45%
  • Status unknown34%
  • Missed its primary endpoint22%
  • Stopped: sponsor or business decision22%
  • Stopped: enrollment or feasibility11%

Trials authorized in Canada

Newest first; search them all in Canada trials
May 16, 2024A phase 3, multicenter, doa phase 3, multicenter, double-blind, randomized, placebo-controlled study of ivosidenib in participants = 18 years of age with…Ivosidenib (AG-120, S95031)ServierOngoing
Apr 23, 2021A phase 2 study of anti-PD-L1 antibody (atezolizumab) in chondrosarcoma and clear cell sarcomaAtezolizumab (MPDL3280A)Princess Margaret Cancer CentrePending

FDA orphan designations

Approved first, then open designations, newest first
May 17, 2023IvosidenibTreatment of ChondrosarcomaServier PharmaceuticalsDesignated
Nov 24, 2021OzekibartTreatment of ChondrosarcomaInhibrx, Inc.Designated
Feb 18, 2011Oral potent and selective antagonistTreatment of patients with chondrosarcoma.Infinity Pharmaceuticals, Inc.Designated

Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA

Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.